Lupin Limited, a leading global pharmaceutical company, has announced that it has received approval from Health Canada for its biosimilar Pegfilgrastim. The product, to be marketed under the brand name Armlupeg®, will be manufactured at Lupin’s Biotech facility in Pune, India.
Pegfilgrastim is a Pegylated version of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim. The prefilled syringes of Pegfilgrastim are indicated for reducing the risk of infection, as evidenced by febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anti-neoplastic drugs.
Nilesh Gupta, Managing Director of Lupin, stated, “We are dedicated to providing affordable and high-quality treatments to our patients. The approval of Armlupeg® by Health Canada enhances our capacity to support Canadian patients with this essential therapy.”
Dr. Cyrus Karkaria, President of Lupin’s Biotech Division, added, “Biosimilars play a crucial role in expanding access to cancer treatment and supportive care. We are pleased to receive our second biosimilar approval in Canada and look forward to continuing this progress with further launches in regulated markets.
About Armlupeg® (pegfilgrastim)
Armlupeg® (pegfilgrastim) is a biosimilar comparable to the reference biologic drug NEULASTA® (pegfilgrastim). It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.Armlupeg® is available in a form of pre-filled syringe of 6mg/0.6 ml.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals.
